Clinical studies indicate that Trigogen supports healthy blood sugar levels in a fasted state and also supports a healthy blood sugar response to a meal.
A new ingredient from Gencor (Irvine, CA) called Trigogen is designed to support metabolic health and glucose levels. The company launched the ingredient during March’s Natural Products Expo West trade show in Anaheim, CA.
Trigogen is a novel, standardized fenugreek seed extract focused on the plant alkaloid compound trigonelline. It is shown to support fasting and postprandial glucose levels.
According to a Gencor press release, “Trigogen’s promising benefits have been shown in a preclinical and a recently published human clinical trial. Gencor’s laboratory study examined how trigonelline may work to support metabolic health and demonstrated an insulin-sensitizing effect. The study revealed that ß-cells (cells within the pancreas responsible for insulin production) attenuated endoplasmic reticulum (ER) stress, which may help support ß-cell health and function. The research also revealed improvement in the antioxidant status of the pancreas.”
In addition, a recently published double-blind, randomized, placebo-controlled human clinical trial demonstrated a significant improvement in fasting blood glucose, 2-hour postprandial glucose response, and triglycerides in subjects who supplemented with Trigogen.1 The 12-week study was performed on 48 adults with “some degree of impaired glucose metabolism.” Subjects took either placebo or 250 mg twice daily of Trigogen.
The results indicate that Trigogen supports healthy blood sugar levels in a fasted state and also supports a healthy blood sugar response to a meal.
In a press release, Ramasamy Venkatesh, cofounder of Gencor and business development specialist, stated, “What makes our product unique is its ability to support healthy pre- and postprandial glucose levels.”
Reference
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.